Your Search Returned 35 tagged news reports
It can be worthwhile to pay attention, as you might get an investment idea or two by seeing what some major investors have been buying and selling. For example, consider Lone Pine Capital, founded by Steve Mandel in 1997. Lone Pine is one of the
Thursday after the company reported quarterly results where revenue for its only FDA-approved drug Soliris increased 37.9%. The company also gave guidance for 2014 that reflects a much higher EPS than what analysts expected. This boost is in part due
Red Hat Inc. surged 14 percent as the software company raised its full-year profit and sales forecasts. Responsys Inc. jumped 40 percent as Oracle Corp. agreed to buy the marketing company for $1.5 billion in cash. CarMax Inc. declined 9.4 percent as
The former tend to drive prices down constantly, innovating all the while in order to make a profit; the latter, by contrast, typically enjoy monopolies that allow them to push up prices without offering anything more in return. Here's another great
Then, place the mixture into an impermeable container that will not let the contents escape under any conditions. Using a jar with a lid or a plastic Ziploc bag are wise choices. Finally, dispose of the container right into the household trash bag...
Earning Catalysts That Could Push This Biotech Even Higher Sherrie is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited...The company is scheduled to report earnings in two
Imagine a world where all the vitamins, minerals, herbs, extracts, compounds, powders, and probiotics that are so freely available at any health food store and at many grocery stores were suddenly made illegal so they could be turned into
Contact Information Available for logged-in reporters only Description To develop new treatment options for patients with SD who failed available options, a Mount Sinai team is examining the central mechanisms of action of a novel oral medication,
Under the agreement, Jazz will develop Concert's deuterium-modified sodium oxybate (D-SXB) compounds, including C-10323, and will have worldwide commercial rights to C-10323 as well as principal responsibility for ongoing development activities.
Jazz shares are trading up more than 30% year-to-date based on Xyrem's strength, but generic competition looms...Restructuring efforts Near the end of 2011, Jazz had two products: narcolepsy treatment Xyrem and obsessive compulsive disorder treatment